BRIDGEBIO PHARMA INC.

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

02 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

18 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

10 янв 2024 17:15:42 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

03 янв 2024 16:30:00 Источник Nasdaq GlobeNewswire

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

03 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

13 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

05 дек 2023 07:45:07 Источник Nasdaq GlobeNewswire

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

09 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

02 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

10 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

09 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

03 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

25 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

06 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

27 авг 2023 06:15:00 Источник Nasdaq GlobeNewswire